Literature DB >> 1396978

A versatile method to produce antibodies to human T cell receptor V beta segments: frequency determination of human V beta 2+ T cells that react with toxic-shock syndrome toxin-1.

F Romagné1, L Besnardeau, B Malissen.   

Abstract

Human V beta (hV beta) regions have been expressed in the context of mouse T cell receptor (TcR)-CD3 complexes, and subsequently used to raise hV beta-specific monoclonal antibodies (mAb). The method of expression of hV beta outlined in this report contrasts in its versatility with the one reported by Choi et al. (Proc. Natl. Acad. Sci. USA 1991. 88: 8357). For instance, we have applied it successfully to the construction of mouse T cell transfectants expressing hV beta 1, hV beta 2, hV beta 3, hV beta 8, hV beta 9, hV beta 13.5, hV beta 19, hV beta 21, and hV beta 22 gene segments. mAb against the hV beta 2 and hV beta 19 regions have been raised by using these transfectants as immunogens in mice. Here, we illustrate the application of the anti-hV beta 2 mAb to the measurement of human T cells that react with the staphylococcal toxic-shock syndrome toxin-1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396978     DOI: 10.1002/eji.1830221043

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Failure of anti-T-cell receptor V beta antibodies to consistently identify a malignant T-cell clone in Sézary syndrome.

Authors:  R D Bigler; C M Boselli; B Foley; E C Vonderheid
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens.

Authors:  B Fleischer; A Necker; C Leget; B Malissen; F Romagne
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Mitogenicity of M5 protein extracted from Streptococcus pyogenes cells is due to streptococcal pyrogenic exotoxin C and mitogenic factor MF.

Authors:  K H Schmidt; D Gerlach; L Wollweber; W Reichardt; K Mann; J H Ozegowski; B Fleischer
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

4.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma.

Authors:  A Mackensen; G Carcelain; S Viel; M C Raynal; H Michalaki; F Triebel; J Bosq; T Hercend
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

5.  Changes in the peripheral blood T-Cell receptor V beta repertoire in vivo and in vitro during shigellosis.

Authors:  D Islam; B Wretlind; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

6.  Superantigen-presentation by rat major histocompatibility complex class II molecules RT1.Bl and RT1.Dl.

Authors:  Henry Dlaske; Hatice Karaüzüm; Elisa Monzon-Casanova; Ronald Rudolf; Lisa Starick; Ingrid Müller; Gerhild Wildner; Maria Diedrichs-Möhring; Norbert Koch; Tohru Miyoshi-Akiyama; Takehiko Uchiyama; Kurt Wonigeit; Bernhard Fleischer; Silke Overbeck; Lothar Rink; Thomas Herrmann
Journal:  Immunology       Date:  2008-12-24       Impact factor: 7.397

7.  Dual T cell receptor beta chain expression on human T lymphocytes.

Authors:  F Davodeau; M A Peyrat; F Romagné; A Necker; M M Hallet; H Vié; M Bonneville
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

8.  Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy".

Authors:  D N Posnett; R Sinha; S Kabak; C Russo
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

9.  Genetic analysis of low V beta 3 expression in humans.

Authors:  J P Donahue; N S Ricalton; C E Behrendt; C Rittershaus; S Calaman; P Marrack; J W Kappler; B L Kotzin
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.